Compare Salesforce Inc (CRM) vs Summit Therapeutics Inc (SMMT) Price & Performance

Salesforce (CRM) trades at $229.13, up 2.04% today, showing strong fundamental performance with consistent earnings beats and robust revenue growth. The company maintains exceptional profitability with 77.28% gross margins and 21.99% net income margins. Technical indicators show a bearish trend with the stock trading near resistance at $230, while analyst consensus remains strongly bullish with a $271.91 price target representing 19% upside potential.

CRM presents a compelling investment opportunity with strong AI monetization growth and improving profitability, though facing near-term technical headwinds and software sector volatility. The stock trades at reasonable valuations (P/E 20.86) with solid cash flow generation, but investors should monitor competitive pressures and macroeconomic impacts on enterprise software spending.

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.